KTX-475

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameKTX-475
Drug Alias NameKTX-475
ClassificationSmall molecules
Mechanisms of ActionInterleukin-1 receptor-associated kinase 4 inhibitorsLipopolysaccharide (LPS) inhibitors
TargetsInterleukin-1 receptor-associated kinase 4Lipopolysaccharide (LPS)
Therapy Area/IndicationsLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKymera Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKymera Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A